NVS Jan 2025 72.500 call
| Previous close | 17.45 |
| Open | 17.45 |
| Bid | 26.50 |
| Ask | 31.00 |
| Strike | 72.50 |
| Expiry date | 2025-01-17 |
| Day's range | 17.45 - 17.45 |
| Contract range | N/A |
| Volume | |
| Open interest | 7 |
ZacksPharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.
- Yahoo Finance Video
Weight loss drug pricing under fire with pills on the horizon
Senior health reporter Anjalee Khemlani joins Brad Smith and Madison Mills on Catalysts to take a look at pharmaceutical stocks like Novartis (NVS) and Novo Nordisk (NVO) as weight loss drug makers are set to meet with lawmakers like Senator Bernie Sanders to discuss pricing. Khemlani provides insight into the weight loss drug market and pricing in the US compared to other countries around the world. She explains that Pfizer (PFE), Eli Lilly (LLY), and Novo are among the candidates who could offer weight loss drugs in pill form rather than through injection, which could transform the market. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Naomi Buchanan.
ZacksNovartis Wins FDA Approval of Kisqali for Early Breast Cancer
The FDA approves NVS' Kisqali to reduce the risk of disease recurrence in patients with HR+/HER2- early breast cancer.
